Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation Wit...(y determined that clinicians were signif...),Health

Date:5/19/2008

y determined that clinicians were significantly more satisfied with the level of sedation achieved with the SEDASYS(TM) System than with current standard of care. Clinicians evaluated sedation administration using the Clinician Satisfaction with Sedation Instrument (CSSI). Additionally, patients sedated with the SEDASYS(TM) System were more satisfied with the sedation they received. Patients evaluated sedation using the Patient Satisfaction with Sedation Instrument (PSSI).

About the SEDASYS(TM) System

The SEDASYS(TM) System is the first computer-assisted personalized sedation (CAPS) system designed for physician/nurse teams to provide minimal to moderate sedation levels with propofol. By integrating drug delivery and patient monitoring, the SEDASYS(TM) System enables physician/nurse teams to deliver personalized sedation. The device continuously monitors and records six patient parameters including oxygen saturation, respiratory rate, heart rate, blood pressure, end-tidal carbon dioxide and patient responsiveness. It automatically detects and responds to signs of over sedation (oxygen desaturation and low respiratory rate/apnea) by stopping or reducing delivery of propofol, increasing oxygen delivery and automatically instructing patients to take a deep breath. The device is currently an investigational device limited by U.S. law to investigational use only.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at http://www.ethiconendo.com .

About DDW

DDW is the largest international gathering of physicians, researchers
'/>"/>

SOURCE Ethicon Endo-Surgery Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
2. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
3. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
4. Arpida Provides Further Comments on the Pivotal Phase III Trials
5. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
6. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
9. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
10. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial